{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T21:10:16Z","timestamp":1731273016923,"version":"3.28.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,10]]},"DOI":"10.7759\/cureus.73393","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T20:33:02Z","timestamp":1731270782000},"source":"Crossref","is-referenced-by-count":0,"title":["Cefepime-Induced Mixed Hepatocellular and Cholestatic Liver Injury: A Case Report"],"prefix":"10.7759","author":[{"given":"Mahyar","family":"Toofantabrizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Timshina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj M","family":"Dongol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani N","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al.. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015, 148:1340-52.e7. 10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2012.18.3.249","article-title":"Drug-induced liver injury: present and future","volume":"18","author":"Suk KT","year":"2012","unstructured":"Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012, 18:249-57. 10.3350\/cmh.2012.18.3.249","journal-title":"Clin Mol Hepatol"},{"key":"ref3","article-title":"Drug-induced liver injury","volume":"6","author":"David S","year":"2010","unstructured":"David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010, 6:73-80.","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade RJ","year":"2005","unstructured":"Andrade RJ, Lucena MI, Fern\u00e1ndez MC, et al.. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005, 129:512-21. 10.1016\/j.gastro.2005.05.006","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"129","author":"De Valle MB","year":"2005","unstructured":"De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bj\u00f6rnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2005, 129:512-21. 10.1111\/j.1365-2036.2006.03117.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben A","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010, 52:2065-76. 10.1002\/hep.23937","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.11.036","article-title":"Identification and characterization of cefazolin-induced liver injury","volume":"13","author":"Alqahtani SA","year":"2015","unstructured":"Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey DC. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015, 13:1328-1336.e2. 10.1016\/j.cgh.2014.11.036","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211015046","article-title":"A case-report of drug-induced mixed liver injury resulting from cefepime exposure","volume":"36","author":"Malhotra K","year":"2023","unstructured":"Malhotra K, Fazylov R, Friedman-Jakubovics M. A case-report of drug-induced mixed liver injury resulting from cefepime exposure. J Pharm Pract. 2023, 36:164-7. 10.1177\/08971900211015046","journal-title":"J Pharm Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/tcmj.tcmj_151_18","article-title":"A rare case of cefepime-induced cholestatic liver injury","volume":"31","author":"Liao PF","year":"2019","unstructured":"Liao PF, Wu YK, Huang KL, Chen HY. A rare case of cefepime-induced cholestatic liver injury. Ci Ji Yi Xue Za Zhi. 2019, 31:124-8. 10.4103\/tcmj.tcmj_151_18","journal-title":"Ci Ji Yi Xue Za Zhi"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade RJ","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, et al.. Drug-induced liver injury. Nat Rev Dis Primers. 2019, 5:58. 10.1038\/s41572-019-0105-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson E","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42:481-9. 10.1002\/hep.20800","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2211","article-title":"Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study","volume":"164","author":"Reuben A","year":"2016","unstructured":"Reuben A, Tillman H, Fontana RJ, et al.. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med. 2016, 164:724-32. 10.7326\/M15-2211","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2015.00052","article-title":"Acetaminophen-induced hepatotoxicity: a comprehensive update","volume":"4","author":"Yoon E","year":"2016","unstructured":"Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016, 4:131-42. 10.14218\/JCTH.2015.00052","journal-title":"J Clin Transl Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana RJ","year":"2014","unstructured":"Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014, 146:914-28. 10.1053\/j.gastro.2013.12.032","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena MI","year":"2011","unstructured":"Lucena MI, Molokhia M, Shen Y, et al.. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011, 141:338-47. 10.1053\/j.gastro.2011.04.001","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27912","article-title":"Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury","volume":"62","author":"Kim SH","year":"2015","unstructured":"Kim SH, Saide K, Farrell J, et al.. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology. 2015, 62:887-99. 10.1002\/hep.27912","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/526379","article-title":"Liver regeneration and aging: a current perspective","volume":"2011","author":"Schmucker DL","year":"2011","unstructured":"Schmucker DL, Sanchez H. Liver regeneration and aging: a current perspective. Curr Gerontol Geriatr Res. 2011, 2011:526379. 10.1155\/2011\/526379","journal-title":"Curr Gerontol Geriatr Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30006-6","article-title":"Drug-induced liver injury in older people","volume":"5","author":"Lucena MI","year":"2020","unstructured":"Lucena MI, Sanabria J, Garc\u00eda-Cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020, 5:826-74. 10.1016\/S2468-1253(20)30006-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.627133","article-title":"Chronic drug-induced liver injury: updates and future challenges","volume":"12","author":"Wang Q","year":"2021","unstructured":"Wang Q, Huang A, Wang JB, Zou Z. Chronic drug-induced liver injury: updates and future challenges. Front Pharmacol. 2021, 12:627133. 10.3389\/fphar.2021.627133","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000374091","article-title":"How to diagnose and exclude drug-induced liver injury","volume":"33","author":"Watkins PB","year":"2015","unstructured":"Watkins PB. How to diagnose and exclude drug-induced liver injury. Dig Dis. 2015, 33:472-6. 10.1159\/000374091","journal-title":"Dig Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22633","article-title":"Using controlled clinical trials to learn more about acute drug-induced liver injury","volume":"48","author":"Watkins PB","year":"2008","unstructured":"Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008, 48:1680-9. 10.1002\/hep.22633","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1378\/chest.68.2.181","article-title":"Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy","volume":"68","author":"Mitchell JR","year":"1975","unstructured":"Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest. 1975, 68:181-90. 10.1378\/chest.68.2.181","journal-title":"Chest"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12988","article-title":"Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications","volume":"36","author":"Dara L","year":"2016","unstructured":"Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016, 36:158-65. 10.1111\/liv.12988","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000250581.77865.68","article-title":"Antibiotic therapy: a major cause of drug-induced jaundice in southwest England","volume":"19","author":"Hussaini SH","year":"2007","unstructured":"Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007, 19:15-20. 10.1097\/01.meg.0000250581.77865.68","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/WNP.0000000000000791","article-title":"Acute toxicity and triphasic waves-the example of cefepime","volume":"39","author":"Husari KS","year":"2022","unstructured":"Husari KS, Ritzl EK, Kaplan PW. Acute toxicity and triphasic waves-the example of cefepime. J Clin Neurophysiol. 2022, 39:419-26. 10.1097\/WNP.0000000000000791","journal-title":"J Clin Neurophysiol"},{"key":"ref26","article-title":"Cefepime induced encephalopathy in a non-dialysis dependent chronic kidney disease patient: a case report","volume":"55","author":"Muniandy G","year":"2023","unstructured":"Muniandy G, Kamaruzaman L, Jan TH, et al.. Cefepime induced encephalopathy in a non-dialysis dependent chronic kidney disease patient: a case report. Acta Med Indones. 2023, 55:78-82.","journal-title":"Acta Med Indones"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000511635","article-title":"Antimitochondrial rather than antinuclear antibodies correlate with severe drug-induced liver injury","volume":"39","author":"Weber S","year":"2021","unstructured":"Weber S, Benesic A, Buchholtz ML, Rotter I, Gerbes AL. Antimitochondrial rather than antinuclear antibodies correlate with severe drug-induced liver injury. Dig Dis Basel Switz. 2021, 39:275-82. 10.1159\/000511635","journal-title":"Dig Dis Basel Switz"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309528","article-title":"Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury","volume":"65","author":"Benesic A","year":"2016","unstructured":"Benesic A, Leitl A, Gerbes AL. Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut. 2016, 65:1555-63. 10.1136\/gutjnl-2015-309528","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13205","article-title":"Mapping the incidence of drug-induced liver injury: a systematic review and meta-analysis","volume":"24","author":"Li M","year":"2023","unstructured":"Li M, Wang Y, Lv TT, Liu JM, Kong YY, Jia JD, Zhao XY. Mapping the incidence of drug-induced liver injury: a systematic review and meta-analysis. J Dig Dis. 2023, 24:332-9. 10.1111\/1751-2980.13205","journal-title":"J Dig Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299036-cefepime-induced-mixed-hepatocellular-and-cholestatic-liver-injury-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T20:33:03Z","timestamp":1731270783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299036-cefepime-induced-mixed-hepatocellular-and-cholestatic-liver-injury-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.73393","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,10]]}}}